Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus anlotinib in taxane-refractory HER2-negative recurrent or metastatic breast cancer
ChiCTR2500104706Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab and anlotinib in breast cancer (3 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoints: Progression-free survival and Recommended Phase II dose (RP2D). Planned start Jun 2025; status: not yet recruiting.
02
Drugs
toripalimabanlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500104706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104706.